Human DHX58 (RLR) knockout A549 cell line
Be the first to review this product! Submit a review
|
(0 Publication)
DHX58 KO cell line available to order. KO validated. Free of charge wild type control available. Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon 4 and 2 bp deletion in exon 4. To order both knockout and wild-type control cells: select '2 x 1000000 Cells/vial'. To order only knockout cells: select '1000000 Cells/vial'.
View Alternative Names
D11LGP2, D11lgp2e, DEXH (Asp Glu X His) box polypeptide 58, DEXH box polypeptide 58, DHX58_HUMAN, LGP 2, Ortholog of mouse D11lgp2, Probable ATP-dependent RNA helicase DHX58, Probable ATP-dependent helicase LGP2, Protein D11Lgp2 homolog, RIG-I-like receptor LGP2, RLR, RNA helicase LGP2
- Cell Culture
Unknown
Cell Culture - Human DHX58 (RLR) knockout A549 cell line (AB266937)
Representative images of DHX58 knockout A549 cells, low and high confluency examples (top left and right respectively) and wild-type A549 cells, low and high confluency (bottom left and right respectively) showing typical adherent, epithelial-like morphology. Images were captured at 10X magnification using a EVOS XL Core microscope.
- Sanger seq
Unknown
Sanger Sequencing - Human DHX58 (RLR) knockout A549 cell line (AB266937)
Allele-1 : 2 bp deletion in exon4
- Sanger seq
Unknown
Sanger Sequencing - Human DHX58 (RLR) knockout A549 cell line (AB266937)
Allele-2 : 1 bp deletion in exon 4.
Product details
We will provide viable cells that proliferate on revival.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.
What's included?
Properties and storage information
Gene name
Gene editing type
Gene editing method
Knockout validation
Shipped at conditions
Appropriate short-term storage conditions
Appropriate long-term storage conditions
Handling procedures
Initial handling guidelines
Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.
1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.
Subculture guidelines
- All seeding densities should be based on cell counts gained by established methods.
- A guide seeding density of 2x104 cells/cm2 is recommended.
- Cells should be passaged when they have achieved 80-90% confluence.
- Do not allow the cell density to exceed 7x104 cells/cm2.
Culture medium
F-12K + 10% FBS
Cryopreservation medium
Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.
Supplementary information
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
DHX58 functions as a regulatory molecule in innate immunity. It usually does not act alone and can form complexes with other RLRs like RIG-I and MDA5. These complexes enhance antiviral signal transduction by modulating downstream components of the interferon signaling pathway. By influencing these pathways DHX58 contributes to the regulation of the immune response ensuring the proper activation of antiviral defense mechanisms.
Pathways
Several immune pathways involve DHX58 namely the RIG-I-like receptor signaling pathway and the interferon regulatory pathways. These pathways are critical for maintaining the body's defense against viral infections. Within these pathways DHX58 interacts with related proteins such as RIG-I and MDA5 which are important for recognizing viral RNA and facilitating subsequent immune responses.
Quality control
STR analysis
CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX
Cell culture
Biosafety level
EU: 1 US: 1
Adherent/suspension
Adherent
Gender
Male
Target data
Complementary Products
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com